Journal of Molecular Pharmaceutics & Organic Process Research
Open Access

COVID-19; SARS-CoV-2; Drug repurposing; Potential drugs; Repurposed drugs; Novel drug targets; Remdesivir; Dexamethasone; Tocilizumab; Ivermectin; Spike protein; Proteases; RNA polymerase

Introduction

The COVID-19 pandemic has presented an urgent need for effective treatments to combat the severe acute respiratory syndrome coronavirus 2 virus. As researchers and healthcare professionals work tirelessly to develop novel therapies and vaccines, drug repurposing has emerged as a promising strategy to expedite the discovery of potential treatments. By leveraging existing drugs that are approved for other indications, the drug repurposing approach offers a faster and more cost-effective route to identifying potential therapies for COVID-19. This article explores the concept of drug repurposing, highlights some promising repurposed drugs, and discusses novel drug targets for COVID-19 treatment [1].

Drug repurposing

Drug repurposing, also known as drug repositioning or drug profiling, involves identifying new therapeutic uses for existing drugs that have already been approved for other medical conditions. This approach takes advantage of the extensive knowledge and safety data available for repurposed drugs, significantly reducing the time and costs associated with the traditional drug development process. In the context of COVID-19, drug repurposing offers the potential to rapidly identify effective treatments by evaluating the efficacy of known drugs against SARS-CoV-2.

Promising repurposed drugs for COVID-19

Several drugs that were initially developed for other diseases have shown potential in treating COVID-19. Here are some notable examples:

Remdesivir: Originally developed for Ebola, remdesivir is a broad-spectrum antiviral drug that inhibits viral replication. Clinical trials have demonstrated its effectiveness in reducing the duration of symptoms in hospitalized COVID-19 patients [2].

Dexamethasone: This corticosteroid has been used for many years to treat various inflammatory conditions. It has shown promising results in reducing mortality rates among severe COVID-19 patients requiring respiratory support.

Tocilizumab: Approved for rheumatoid arthritis, tocilizumab is a monoclonal antibody that targets the interleukin-6 receptor. By modulating the immune response, tocilizumab has demonstrated potential in managing severe inflammation associated with COVID-19.

Ivermectin: Originally developed as an antiparasitic drug, ivermectin has exhibited antiviral activity against SARS-CoV-2 in laboratory studies. However, further clinical trials are needed to establish its efficacy and safety in COVID-19 patients [3].

Novel drug targets for COVID-19

In addition to repurposing existing drugs, researchers are actively exploring novel drug targets that specifically inhibit SARS-CoV-2 infection or mitigate its severe effects. Here are a few examples: Spike protein and ACE2 receptor interaction: The spike protein of SARS-CoV-2 plays a crucial role in viral entry into human cells.

Targeting the interaction between the spike protein and the ACE2 receptor has been explored as a potential therapeutic approach.

Protease inhibitors: SARS-CoV-2 relies on specific proteases to process viral proteins necessary for replication. Inhibiting these proteases, such as the main protease and the papain-like protease, could potentially impede viral replication [4].

RNA-dependent RNA polymerase (RdRp): SARS-CoV-2 RdRp is a key enzyme responsible for viral RNA replication. Developing inhibitors that target RdRp could disrupt viral replication and reduce viral load.

Host immune response modulation: Modulating the immune response to prevent the excessive inflammation seen in severe COVID-19 cases is another target of interest. This includes exploring immunomodulatory drugs or monoclonal antibodies targeting cytokines involved in the cytokine storm [5].

Discussion

The COVID-19 pandemic has prompted an urgent need for effective treatments against the SARS-CoV-2 virus. While the development of new drugs typically involves a lengthy and costly process, drug repurposing offers a viable approach to expedite the identification of potential treatments. By leveraging existing drugs that have already been approved for other indications, researchers can bypass certain stages of the drug development process, saving time and resources [6]. Drug repurposing for COVID-19 involves screening existing drugs to assess their potential effectiveness against the SARS-CoV-2 virus. This strategy takes advantage of the extensive knowledge and safety data available for these drugs, allowing researchers to focus on their antiviral activity or immunomodulatory properties against COVID-19. Several repurposed drugs have shown promise in treating COVID-19.One of the most notable repurposed drugs is remdesivir, originally developed for Ebola. Remdesivir is a broad-spectrum antiviral drug that inhibits viral replication by targeting the RNA-dependent RNA polymerase. Clinical trials have demonstrated its effectiveness in reducing the duration of symptoms in hospitalized COVID-19 patients. It has received emergency use authorization in several countries [7].

Dexamethasone, a well-known corticosteroid, has also shown promising results in COVID-19 treatment. It is primarily used for its anti-inflammatory properties and has been found to reduce mortality rates among severe COVID-19 patients requiring respiratory support. Dexamethasone helps mitigate the excessive immune response and inflammation associated with severe cases of the disease [8].

Tocilizumab, originally approved for rheumatoid arthritis, is a monoclonal antibody that targets the interleukin-6 receptor. IL-6 is a cytokine involved in the inflammatory response. Tocilizumab has demonstrated potential in managing the severe inflammation seen in some COVID-19 patients. It has been used in clinical trials to treat severe cases with promising results, although further research is needed to establish its efficacy and safety.

Ivermectin, an antiparasitic drug, has shown antiviral activity against SARS-CoV-2 in laboratory studies. It has been investigated as a potential treatment for COVID-19, particularly in low-resource settings. However, the efficacy and safety of ivermectin in treating COVID-19 remain controversial, and further clinical trials are needed to provide definitive evidence [9].

In addition to repurposed drugs, researchers are actively exploring novel drug targets for COVID-19 treatment. These targets aim to directly inhibit the virus or modulate the host immune response to mitigate the severe effects of the disease. Some of the key targets being investigated include:

Spike protein and ACE2 receptor interaction: The spike protein of SARS-CoV-2 plays a crucial role in viral entry into human cells. Researchers are exploring ways to disrupt the interaction between the spike protein and the ACE2 receptor as a potential therapeutic approach. Protease inhibitors: SARS-CoV-2 relies on specific proteases for viral replication. Inhibiting these proteases, such as the main protease and the papain-like protease, could potentially impede viral replication and reduce viral load.

RNA-dependent RNA polymerase (RdRp): SARS-CoV-2 RdRp is responsible for viral RNA replication. Developing inhibitors that target RdRp could disrupt viral replication and reduce viral load.Host immune response modulation: Modulating the immune response to prevent the excessive inflammation seen in severe COVID-19 cases is another target of interest [10, 11].

Conclusion

The drug repurposing approach has provided a valuable means of identifying potential treatments for COVID-19 in a time-critical manner. Repurposed drugs such as remdesivir, dexamethasone, tocilizumab, and ivermectin have shown promise in managing the disease. Meanwhile, researchers are also exploring novel drug targets, including the spike protein, proteases, RNA polymerase, and immunomodulatory pathways. However, rigorous clinical trials and further research are necessary to establish the efficacy and safety of these drugs and targets for COVID-19 treatment. With ongoing efforts, drug repurposing and novel drug target exploration hold the potential to provide effective therapeutic options to combat the COVID-19 pandemic and enhance global healthcare resilience in the face of future infectious diseases.

Conflict of Interest

None

Acknowledgement

None

1. Berardinelli W (1954) An undiagnosed endocrinometabolic syndrome.  J Clin Endocr 14: 193-204.

Google Scholar, Crossref, Indexed at

2. Seip M, Trygstad O (1963) Generalized lip dystrophy. Ital J Pediatr 38: 447-453.

Google Scholar, Crossref, Indexed at

3. Windpassinger C, Auer-Grumbach M, Irobi J (2004) Heterozygous missense mutations in BSCL2 is associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 36: 271-276.

Google Scholar, Crossref, Indexed at

4. Garfield AS, Chan WS, Dennis RJ, Ito D, Heisler LK, et al. (2012) Neuroanatomical characterization of the expression of the lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse brain. PLoS One 7: 9.

Google Scholar, Crossref, Indexed at

5. Stingl K, Bartz-Schmidt KU, Besch D (2013) Artificial vision with wirelessly powered subretinal electronic implant alpha-IMS. Proc R Soc B Biol Sci 280: 201-206.

Google Scholar, Crossref, Indexed at

6. Besch D, Sachs H, Szurman P (2008) Extraocular surgery for implantation of an active subretinal visual prosthesis with external connections: feasibility and outcome in seven patients. Br J Ophthalmol 92: 1361-1368.

Google Scholar, Crossref, Indexed at

7. Sachs H, Bartz-Schmidt KU, Gabel VP, Zrenner E, Gekeler F, et al. (2010) Subretinal implant: the intraocular implantation technique.  Nova Acta lopa 379: 217-223.

Google Scholar  

8. Balkany TJ, Whitley M, Shapira Y (2009) The temporalis pocket technique for cochlear implantation: an anatomic and clinical study. Otol Neurotol 30: 903-907.

Google Scholar, Crossref, Indexed at

9.  Donoghue GM, Nikolopoulos TP (2002) Minimal access surgery for pediatric cochlear implantation. Otol Neurotol23: 891-894.

Google Scholar, Crossref, Indexed at

10. Stingl K, Bartz-Schmidt KU, Besch D (2015) Subretinal visual implant alpha IMS-clinical trial interim report. Vis Res 111: 149-160.

Google Scholar, Crossref, Indexed at

11. Cosyn J, Wessels R, Garcia Cabeza R, Ackerman J, Eeckhout C, et al. (2021) Soft tissue metric parameters, methods and aesthetic indices in implant dentistry: a critical review. Clin Oral Implants Res 32: 93-107.

Google Scholar, Crossref, Indexed at